Circio enters in vivo cell therapy collaboration with United Immunity

26 Mar 2026 13:40 CET

* United Immunity and Circio has initiated a collaboration in the area of in
vivo cell therapy
* Circio s circVec circular RNA expression system will be tested together with
United s P-LNP delivery technology targeting myeloid cells, such as
macrophages and dendritic cells
* The aim of the collaboration is to assess whether circVec can prolong gene
expression and be deployed to enhance United s CAR-M in vivo therapies

Oslo, Norway, 26 March 2026 -- Circio Holding ASA (OSE: CRNA), a biotechnology
company developing novel circular RNA expression technology for gene and cell
therapy, today announces that it has entered a research collaboration in the
area of in vivo CAR-Macrophage (CAR-M) therapy with United Immunity Co., Ltd.,
based in Tokyo, Japan.

Circio has previously demonstrated that its proprietary circVec circular RNA
expression technology can substantially enhance and prolong the activity of
conventional gene and cell therapy approaches. In this new collaboration,
United Immunity will test whether circVec can be delivered with its P-LNP
platform to target myeloid immune cells and extend payload expression. The aim
is to determine the therapeutic potential of combining the circVec and P-LNP
technologies for in vivo CAR-M, a novel therapeutic approach against cancer,
fibrosis, and autoimmune disorders.

"In vivo cell therapy is currently an extremely active development field
highlighted by several recent strategic transactions, including two circular
RNA companies" said Dr. Victor Levitsky, CSO of Circio. "United Immunity has a
very interesting and clearly differentiated drug delivery approach targeting
immune cells in the tumor, which we mutually believe can act synergistically
with Circio s circVec circular RNA expression technology. If the combination
works as expected, the collaboration may lead to the generation of a joint
platform for completely novel CAR-M in vivo therapies."

For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@circio.com

Neil Hunter -- Hunter PR
Phone: +44 782 125 5568
Email: neiljameshunter@gmail.com

About Circio
Building circular RNA expression systems for enhanced gene and cell therapies

Circio Holding ASA is a biotechnology company developing novel circular RNA
expression technology for gene and cell therapy.

Circio has established a unique circular RNA (circRNA) vector expression
technology for next generation RNA, DNA and viral therapeutics. The
proprietary circVec platform is based on a modular genetic construct designed
for efficient biogenesis of multifunctional circRNA inside target cells. The
circVec platform has applications in multiple therapeutic settings, including
genetic medicine, cell therapy and chronic disease. It has demonstrated
75-fold increased RNA half-life and up to 40-fold enhanced protein expression
vs. conventional mRNA-based viral and non-viral vector systems, with the
potential to become a new gold-standard gene expression technology. The
circVec R&D activities are being conducted by the wholly owned subsidiary
Circio AB in Stockholm, Sweden.

More information:
Access the news on Oslo Bors NewsWeb site